Healthcare-Associated Infections
Learning Objectives
Introduction
At the end of this module, the learner will be able to:
- Describe the adverse health and economic consequences of healthcare-associated infections.
- Summarize how surveillance of healthcare-associated infections is performed and how these data can be used for local quality-improvement activities.
- Discuss how public reporting of healthcare-associated infection data is being implemented and used by healthcare consumers and payers.
Device Associated Infections
At the end of this module, the learner will be able to:
- Describe the pathogenesis of CLABSI, CAUTI and VAP.
- List the most effective strategies to prevent CLABSI, CAUTI and VAP.
- Explain the difference between surveillance definitions for device-associated infections and the clinical syndromes, and explain why the difference exists.
Multidrug-Resistant Organisms: MRSA, CRE, VRE, ESBL
At the end of this module, the learner will be able to:
- State the definition of multidrug resistance, common mechanisms of resistance, and identify organisms which are typically classified as Multidrug-Resistant Organisms (MDROs).
- Compare and contrast the differences in resistance testing conducted using phenotypic and genotypic methods.
- Identify the impact of common Multidrug-Resistant Organisms (MDROs) in the care of hospitalized patients.
- Describe the differences between vertical and horizontal transmission, and discuss the interventions that prevent the emergence and spread of MDROs.
C. difficile
At the end of this module, the learner will be able to:
- Summarize risk factors for C. difficile infection
- Discuss testing strategies for detecting C. difficile infection including limitations and factors which may impact testing outcomes
- Describe transmission-based precautions and environmental cleaning practices to prevent the spread of C. difficile
Surgical Site Infections
At the end of this module, the learner will be able to:
- Define the frequency and impact of SSI.
- Describe the epidemiology and risk factors of SSI.
- Identify prevention strategies especially as they impact physicians in training.
Introduction
Original Author:
Christopher Crnich, MD
Associate Professor of Medicine
University of Wisconsin School of Medicine & Public Health
No relevant financial disclosures
Device Associated Infections
Associate Professor of Medicine
Columbia University Medical Center
No relevant financial disclosures
Multidrug-Resistant Organisms: MRSA, CRE, VRE, ESBL
Wayne State University
No relevant financial disclosures
Infectious Disease Fellow
Wayne State University
No relevant financial disclosures
Professor of Community Medicine,
Dayanand Medical College & Hospital
No relevant financial disclosures
Professor of Medicine
Wayne State University
No relevant financial disclosures
Revising Authors (2019):
Teena Chopra, MD, MPH
Infectious Disease Fellow
Wayne State University
Consulting Fee: Shinogi, Tetraphase;
Speakers Bureau: Allergan, Merck
All of the relevant financial relationships listed have been mitigated
David Banach, MD, MPH
Associate Professor of Medicine
UConn Health
No relevant financial disclosures
C. difficile
Original Authors:
UConn Health
No relevant financial disclosures
Sarah Haessler, MD, MS
Associate Professor
University of Massachusetts Medical School-Baystate
No relevant financial disclosures
Sarit Sharma, MD
Professor of Community Medicine,
Dayanand Medical College & Hospital
No relevant financial disclosures
Revising Authors (2023):
No relevant financial disclosures
No relevant financial disclosures
No relevant financial disclosures
Surgical Site Infections
Original Author:
Trish Perl, MD, MSc
Jay P Sanford Professor of Medicine
UTSouthwestern Medical Center
No relevant financial disclosures
Revising Author (2019):
Julie Trivedi, MD
Medical Director of Infection Prevention
UTSouthwestern Medical Center
No relevant financial disclosures